Clinical trials: Pneumonia; Pulmonary Infection
SARS-CoV2 Infection
Efficacy and Safety of EXOSOME-MSC Therapy to Reduce Hyper-inflammation In Moderate COVID-19 Patients
In COVID-19 infection caused by the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is a dysregulation of the immune system response that causes cytokine storm syndrome.
- Trial name
- EXOMSC-COV19 (NCT05216562)
- Testing
- Exosome-MSC Intravenous injection, COVID-19 Standard Treatment
- Where
- 3 sites in Indonesia
- Volunteers
- 60 people
- Sponsor
- Dermama Bioteknologi Laboratorium
Malaria, Pneumonia
Text Message Reminders to Health Workers on Malaria, Pneumonia, and Diarrhea Case Management in Malawi
The purpose of this study is to assess whether twice-daily text message reminders over a six-month period to health workers in Malawi about diagnosis and treatment of malaria, pneumonia, and diarrhea improve case management of…
- Conditions
- Malaria, Pneumonia, Diarrhea
- Trial name
- NCT02645513
- Testing
- Malaria text message reminders to health workers, Malaria, pneumonia, and diarrhea text message reminders to health workers, Control
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Trauma, Covid19
The Impact of COVID-19 Pandemic to Trauma Patients in Emergency Department: A Multicenter Experience of Istanbul
COVID-19, which emerged in China in December 2019, has become a pandemic with its spread to many countries of the world. The aim of this multi-centered study is to guide for the approach, organization, diagnosis and treatment of…
- Trial name
- NCT04479124
- Testing
- COVID-19 PCR
- Where
- Turkey (Türkiye)
- Volunteers
- 2,000 people
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
Covid19
Test to Stay in School: COVID-19 Testing Following Exposure in School Communities
Participants in school communities who have been exposed to SARS-CoV-2 will be tested for COVID-19 on the day of exposure (day 1) and at days 3, 5, and 7 following initial known exposure.
- Trial name
- NCT05052580
- Testing
- COVID-19 Testing
- Where
- United States
- Volunteers
- 4,733 people
- Sponsor
- Duke University
PTSD, PTSD Symptoms
Virtual Reality Treatment for Trauma Related to COVID-19 Infection
This clinical trial aims to develop and evaluate the effectiveness of virtual reality (VR)-based exposure therapy for trauma symptoms related to COVID-19 infection.
- Trial name
- NCT07213596
- Testing
- VR Exposure Therapy, Cognitive Behavioral Therapy (CBT), Supportive Psychotherapy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Soonchunhyang University Hospital
COVID-19, Pneumonia
Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)
This study adopts a randomized, double-blind, placebo parallel control design, and is expected to include 168 eligible patients with severe novel coronavirus pneumonia.
- Trial name
- COVID-19 (NCT05702788)
- Testing
- Jaktinib hydrochloride tablets
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Post-Acute COVID-19, Post Acute COVID-19 Syndrome
Safety and Dosage of a Computerized Cognitive Training Program for Cognitive Dysfunction After COVID-19
The goal of this Phase I/II clinical trial is to assess the safety and maximum tolerated training time of a self-administered computerized cognitive training (CCT) in individuals with cognitive dysfunction as a consequence of…
- Conditions
- Post-Acute COVID-19, Post Acute COVID-19 Syndrome, Cognitive Dysfunction, Cognitive Impairment
- Trial name
- CCTLongCOVID (NCT05582603)
- Testing
- CCT Long COVID
- Where
- Spain
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Universidad Antonio de Nebrija
COVID-19, SARS-CoV-2 Acute Respiratory Disease
Safety, Tolerability and Immunogenicity of Gam-COVID-Vac Vaccine in a Nasal Spray
Randomized, double-blind, placebo-controlled trial to evaluate safety and immunogenicity of intranasal "Gam-COVID-Vak" combined vector vaccine for the prevention of coronavirus infection caused by the SARS-CoV-2 virus.
- Trial name
- SPRAY (NCT05248373)
- Testing
- Gam-COVID-Vac
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Allogeneic Stem Cell Transplantation, SARS-CoV2 Infection
Impact of COVID-19 Pandemic on Allogeneic Stem Cell Transplantation Organization : a French Experience
the SARS-CoV2 pandemic has led to a major reorganization of the French Hematology and stem cell transplant departments since march 2020.
- Conditions
- Allogeneic Stem Cell Transplantation, SARS-CoV2 Infection, COVID-19
- Trial name
- covidallo (NCT05088941)
- Where
- France
- Volunteers
- 89 people
- Sponsor
- Central Hospital, Nancy, France
Covid19, C-reactive Protein
Early Predictors of Prognostic Course in Patients With COVID-19 in Critical or Semi-intensive Area.
Although the recent literature is building a remarkable background to answer the many unknowns related to SARS-CoV-2 infection, it is absolutely necessary to finalize every clinical effort to collect data that may be useful, in a…
- Conditions
- Covid19, C-reactive Protein, Procalcitonin, D-dimer
- Trial name
- NCT04873388
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- University of Turin, Italy
COVID-19 Pandemic, Dyspnea; Cardiac
Covid-19 Infection and Long-term Cardiovascular Symptoms
From the registry of professor Kojuri clinic , those with Covid-19 infection were selected and was contacted and asked about the cardiovascular symptoms, 1 year after the covid infection
- Conditions
- COVID-19 Pandemic, Dyspnea; Cardiac, Chest Syndrome, Functional Cardiac Disorder
- Trial name
- NCT05715879
- Testing
- covid infection, admission to hispital
- Where
- Iran
- Volunteers
- 879 people
- Sponsor
- Shiraz University of Medical Sciences
COVID-19
Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19
The aim of this project is to introduce way for treatment of patients with severe COVID-19 disease with respiratory complications.
- Trial name
- COVID-19 (NCT04376788)
- Testing
- exchange blood transfusion from normal donor, plasma from convalescent patients with COVID-19, Methylene Blue 5 MG/ML
- Where
- Egypt
- Volunteers
- 15 people
- Sponsor
- Ain Shams University
COVID-19, Endothelial Function
Diagnostics of Coronavirus Disease 2019 Cardiovascular Complications
Aim of this prospective, observational, multi-centered, randomized study is to detect cardiovascular complications in patients after coronavirus infection.
- Conditions
- COVID-19, Endothelial Function, Diastolic Dysfunction, Oxygen Consumption
- Trial name
- NCT05608603
- Testing
- Portable cardiac monitor "CardioQvark", Cardiorespiratory stress test, Analysis of exhaled air using the Compact PTR-MS proton mass spectrometer
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
COVID 19
B Cell Responses in COVID-19
In this study, we will develop techniques to optimize the in vitro production of human monoclonal antibodies.
- Trial name
- NCT06891170
- Where
- Italy
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Covid19, Hypoxemic Respiratory Failure
Endothelial Dysfunction in Covid-19
SARS-CoV-2 targets endothelial cells via the angiotensin-converting enzyme 2 receptor. The specific impact of the resulting endothelial injury is currently unknown but may contribute to the pro-coagulant state classically…
- Trial name
- ENDOCOVID (NCT04830683)
- Where
- Belgium
- Volunteers
- 85 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Streptococcus Pneumoniae Pneumonia
Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
In the treatment of pneumococcal diseases, the common use of penicillin-based antimicrobial agents has led to drug resistance, which has become a global challenge. Therefore, disease prevention through vaccination is essential.
- Trial name
- NCT07035054
- Testing
- low dose-1, low dose-2, high dose
- Where
- China
- Volunteers
- 992 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
COVID-19
COVID-19 Booster Study in Healthy Adults in Australia
This is a double-blinded, randomised study to determine the safety, reactogenicity, and immunogenicity of a bivalent mRNA Moderna COVID-19 vaccine or a protein-based Novavax COVID-19 vaccine given as a fourth dose in healthy…
- Trial name
- NCT05658523
- Testing
- Bivalent Moderna, Novavax
- Where
- Australia
- Volunteers
- 496 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Covid19
Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting
No therapeutic agent is currently approved for the treatment of SARSCoV-2 infection. More importantly, no intervention is currently available to mitigate the progression of disease from mid/moderate to serve particularly in high…
- Trial name
- NCT04840459
- Testing
- BAMLANIVIMAB, CASIRIVIMAB, IMDEVIMAB
- Where
- 3 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Sohail Rao
Normobaric Hypoxia, Hypoventilation
Influence of Hypoxic, Normobaric and Hypobaric Training on the Immunometabolism of Post-covid-19 Athletes
COVID-19 has significantly impacted sports globally, with event postponements, training disruptions, and wide-ranging concerns. SARS-CoV-2 infection can result in hyperinflammation and cardiopulmonary changes, with hypoxia as an…
- Conditions
- Normobaric Hypoxia, Hypoventilation, Normoxia
- Trial name
- NCT06128941
- Testing
- Repeated sprint
- Where
- Portugal
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Faculdade de Motricidade Humana
Infections, Streptococcal, Streptococcus Pneumoniae
Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease
The aim of this study is to assess the effectiveness of GSK Biologicals' pneumococcal conjugate vaccine (GSK1024850A), administered according to different vaccination schedules, against invasive disease caused by S.
- Trial name
- FinIP (NCT00861380)
- Testing
- Pneumococcal conjugate vaccine GSK1024850A, GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine), GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)
- Where
- Finland
- Volunteers
- 41,188 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.